Phase I trial of AKB 6899 in patients with cancer

Trial Profile

Phase I trial of AKB 6899 in patients with cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 23 May 2016

At a glance

  • Drugs AKB 6899 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Akebia Therapeutics
  • Most Recent Events

    • 23 May 2016 According to an Akebia Therapeutics media release, the company expected to commence clinical development of AKB-6899 in 2016.
    • 14 Mar 2016 According to an Akebia Therapeutics media release, the company has opened an Investigative New Drug Application with the US FDA for AKB-6899 for treatment of cancer.
    • 04 Jan 2016 According to an Akebia Therapeutics media release, this trial is expected to being in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top